2025年08月05日 星期二 首页   |   期刊介绍   |   编 委 会   |   投稿指南   |   期刊订阅   |   广告合作   |   联系我们   |   ENGLISH
哈尔滨医药  2022, Vol. 42 Issue (1): 1-4    DOI: 10.3969/j.issn.1001-8131.2022.01.001
  论著 本期目录 | 过刊浏览 | 高级检索 |
小剂量尿激酶治疗急性轻型脑梗死的临床研究
蓝少勇, 林东, 苏斌儒
东莞市第八人民医院神经内科,广东 东莞 523000
Clinical Study of Low-Dose Urokinase in the Treatment of Acute Mild Cerebral Infarction
Lan Shaoyong, Lin Dong, Su Binru
Department of Neurology,Dongguan Eighth People's Hospital,Dongguan 523000,China
全文: PDF (488 KB)   HTML (1 KB) 
输出: BibTeX | EndNote (RIS)      
摘要 目的 研究临床急性脑梗死患者采用小剂量尿激酶治疗的临床效果。方法 选取50例脑梗死患者进行研究,分为研究组和常规组,每组25例。两组均持续治疗2周,计算两组的总有效率,采用神经功能缺损评分量表(NIHSS)以及改良Rankin评分、Barth指数(BI)、日常生活活动量表(ADL)分别对患者的神经功能以及生活质量、日常生活能力进行评定。比较治疗前后患者的血浆黏度、高切及低切两项全血黏度、纤维蛋白原(FIB)水平。结果 治疗后90d研究组NIHSS评分情况以及改良Rankin(mRS)评分情况水平均远优于常规组(P<0.05)。两组患者的并发症发生率差异无统计学意义(P>0.05)。比较两组的日常生活能力及生活质量情况,研究组均远优于常规组(P<0.05)。对比两组患者治疗前后的血小板计数变化,研究组治疗前后该指标水平差异有统计学意义(P<0.05)。常规组患者治疗前后的血小板计数差异无统计学意义(P>0.05)。对比治疗前后两组患者的红细胞压积变化情况,两组患者相比于治疗前其红细胞压积数值均出现一定幅度的下降,研究组下降幅度远高于常规组,该组治疗前后红细胞压积水平差异有统计学意义(P<0.05)。结论 临床采用小剂量尿激酶治疗可使急性脑梗死患者的疗效得到显著提高,提高患者治疗安全性,具有较高的临床推广价值。
服务
把本文推荐给朋友
加入我的书架
加入引用管理器
E-mail Alert
RSS
作者相关文章
蓝少勇
林东
苏斌儒
关键词 尿激酶急性轻型脑梗死神经功能缺损评分量表    
AbstractObjective To study the clinical effect of low-dose urokinase in patients with acute cerebral infarction. Methods 50 patients were selected for study,divided into study group and routine group,25 cases in each group.Both groups were treated for 2 weeks,and the total effective rate was calculated.The neurological deficit score scale(NIHSS)and the modified Rankin score,Barth index(BI),and activity of daily living(ADL)were used to treat the patient's nerves.The function,as well as the quality of life and daily living ability,are assessed.The plasma viscosity,high and low cut whole blood viscosity,and fibrinogen(FIB)levels were compared before and after treatment. Results After comparison,the NIHSS score and the improved Rankin(mRS)score of the study group were much better than the conventional group 3 months after treatment,P<0.05,the difference between the groups was statistically significant.There was no significant difference in the incidence of complications between the two groups,P>0.05,the difference was not statistically significant.The daily living ability and quality of life of the two groups were compared.The study group was far superior to the conventional group,P<0.05,and the difference was statistically significant.The changes of platelet counts before and after treatment in the two groups were compared.There were significant differences in the levels of the indicators before and after treatment in the study group,P<0.05.has statistical significane.There was no significant difference in platelet counts between the conventional group before and after treatment,P>0.05,and the difference was not statistically significant.Comparing the changes of hematocrit in the two groups before and after treatment,the hematocrit values of the two groups were lower than the treatment before treatment.The decline of the study group was much higher than that of the conventional group.There was a significant difference in the levelofcompressio,P<0.05,thedifference was statistically significant. Conclusion The clinical use of low-dose urokinase can significantly improve the efficacy of patients with acute cerebral infarction,improve the safety of patients,and has a high clinical value.
Key wordsUrokinase    Acute mild cerebral infarction    Neurological deficit score scale
收稿日期: 2020-12-12     
PACS:  R743.33  
基金资助:广东省东莞市社会科技发展项目(201950715028625)
引用本文:   
蓝少勇, 林东, 苏斌儒. 小剂量尿激酶治疗急性轻型脑梗死的临床研究[J]. 哈尔滨医药, 2022, 42(1): 1-4.
Lan Shaoyong, Lin Dong, Su Binru. Clinical Study of Low-Dose Urokinase in the Treatment of Acute Mild Cerebral Infarction. journal1, 2022, 42(1): 1-4.
链接本文:  
http://www.hrbyybjb.org.cn/CN/10.3969/j.issn.1001-8131.2022.01.001     或     http://www.hrbyybjb.org.cn/CN/Y2022/V42/I1/1
版权所有 © 《哈尔滨医药》编辑部  备案号: 黑ICP备19005758号-1
本系统由北京玛格泰克科技发展有限公司设计开发 技术支持:support@magtech.com.cn